Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

NCT00542451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

406

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Carcinoma of the Breast

Interventions

DRUG: Paclitaxel
DRUG: Trastuzumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]